Siegfried Holding
Dr. Dan Byrom is an experienced professional in business development and sales within the pharmaceutical sector, currently serving as the Director of Business Development for the API Portfolio at Siegfried Holding AG since September 2022. Prior to this role, Dan held the position of Area Sales Manager at UQUIFA, focusing on the sales of a full portfolio of APIs in Europe, and at IMCD Group, which followed an acquisition of DCS Pharma AG. Dan's career began at Enantia, S.L. as an Account Manager, and prior academic experience includes a PhD at IRB Barcelona, where research involved the scale-up of P-chiral phosphine ligands for asymmetric catalysis. Dan holds a Master of Research in Green Chemistry from Imperial College London and a Bachelor of Science in Chemistry from Newcastle University.
This person is not in any teams
Siegfried Holding
1 followers
Siegfried Holding AG is a Switzerland-based life sciences company and active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States and China.